Head & Neck Cancers | Specialty

Dr. Tolaney Highlights New Breast Cancer Combination Therapies

June 2nd 2019

ASCO 2019: Dr. Monk on Promising Abstracts in Gynecologic Malignancies

June 2nd 2019

ASCO 2019: Dr. Horn Highlights Progress in Lung Cancer

June 2nd 2019

ASCO 2019: Dr. Shah Covers Potentially Practice-Changing GI Cancer Studies

June 2nd 2019

ASCO 2019: Dr. Tagawa Highlights Key Prostate Cancer Data

June 2nd 2019

ASCO 2019: Dr. Rajkumar Highlights Practice-Changing Multiple Myeloma Studies

June 2nd 2019

OncLive News Network On Location: In Chicago Tuesday, June 4

June 2nd 2019

OncLive News Network On Location: In Chicago Monday, June 3

June 2nd 2019

OncLive News Network On Location: In Chicago Sunday, June 2

June 2nd 2019

OncLive News Network On Location: In Chicago Saturday, June 1

June 2nd 2019

Addressing Unmet Needs in Medullary Thyroid Cancer

June 1st 2019

Rozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses unmet needs in medullary thyroid cancer.

Dr. Cohen on the Era Before Immunotherapy in Head and Neck Cancer

May 29th 2019

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the treatment era before immunotherapy in head and neck cancer.

Montefiore Study May Help Establish Patient Criteria for Proton Therapy

May 21st 2019

In an effort to build more sophisticated protocols that keep QoL and cost questions at the forefront, Montefiore Einstein Center for Cancer Care and Albert Einstein College of Medicine’s Institute for Onco-Physics created a mathematical model to identify the optimal candidates for proton therapy, the most modern form of radiation therapy for patients with head and neck cancers.

Staging System for HPV-Related Oropharynx Cancer Paves Way for Change

May 13th 2019

A new staging system for head and neck cancers recognizes that patients with oropharyngeal malignancies associated with the human papillomavirus often have an excellent prognosis, but efforts to deintensify therapy for this population based on a fresh understanding of favorable risk factors may be premature.

Dr. Burtness on the Use of Biomarkers in Metastatic HNSCC

April 29th 2019

Barbara Burtness, MD, professor of Medicine (Medical Oncology) Disease Aligned Research Team Leader, Head and Neck Cancers Program co-director, Developmental Therapeutics Research Program of Yale Cancer Center, discusses the use of biomarkers in metastatic head and neck squamous cell carcinoma.

Fee-for-Service Unlikely to Disappear Soon

April 15th 2019

Fee-for-service tends to result in a surplus of care and unnecessary medical expense, but it probably won’t disappear from the landscape soon.

Dr. Mehanna on the Design of the De-ESCALaTE Trial in HPV+ Head and Neck Cancer

April 11th 2019

Hisham Mehanna, PhD, BMedSc, MBChB, FRCS, chair, Head and Neck Surgery, director, Institute of Head and Neck Studies and Education at the Institute of Cancer and Genomic Sciences, University of Birmingham, discusses the design of the De-ESCALaTE trial in patients with HPV-positive head and neck cancer.

Dr. Cohen on the Value of PFS as an Endpoint in Head and Neck Cancer

April 5th 2019

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses the value of progression-free survival (PFS) as an endpoint in head and neck cancer trials.

Dr. Burtness on Promise of Frontline Pembrolizumab in Metastatic HNSCC

March 30th 2019

Barbara Burtness, MD, professor of Medicine (Medical Oncology); Disease Aligned Research Team Leader, Head and Neck Cancers Program; co-director, Developmental Therapeutics Research Program; of Yale Cancer Center, discusses the promise of frontline pembrolizumab in the treatment of patients with metastatic head and neck squamous cell carcinoma.

EU Panel Backs Extended Pembrolizumab Dosing Schedule for Single-Agent Indications

March 5th 2019

The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for a new extended dosing schedule for pembrolizumab for all of the PD-1 inhibitor’s monotherapy indications in the European Union.